The FDA on June 15, 2020 granted accelerated approval to ZEPZELCA® for adult patients with metastatic Small Cell Lung Cancer (SCLC), with disease progression on or after platinum-based chemotherapy. ZEPZELCA® is a product of Pharma Mar S.A.
Bottom Ad
Advertisement
Subscribe
